Steven Sorci, DO
Advanced Heart Failure and Transplant Cardiology · Brooklyn, NYNPI 1598170870
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,350 of the $36,270 with a category attached, or 61.6%. AstraZeneca accounts for 69.3% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $25,187, more than ten times the $1,384 reported in 2019.
Across 315 payments — averaging $115.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$25K
- Abbott$4K
- Cvrx, Inc.$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$877
- Abiomed$667
- Medtronic$615
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$22,35062%
- Travel & lodging$2,5827%
- Food & beverage$10,79130%
- Education$5482%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $25,124 |
| Abbott | 51 | $3,871 |
| Cvrx, Inc. | 13 | $1,354 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 29 | $877 |
| Abiomed | 12 | $667 |
| Medtronic(2 entities) | 9 | $615 |
| Impulse Dynamics (USA) Inc. | 4 | $462 |
| Novartis | 21 | $363 |
| Bridgebio Pharma, Inc. | 23 | $323 |
| Actelion Pharmaceuticals US, Inc. | 5 | $268 |
| Boehringer Ingelheim | 16 | $264 |
| Merck | 13 | $258 |
| United Therapeutics Corporation | 3 | $246 |
| Alnylam Pharmaceuticals Inc. | 7 | $235 |
| ZOLL Respicardia, Inc. | 2 | $213 |
| Lexicon Pharmaceuticals, Inc. | 7 | $149 |
| Boston Scientific | 3 | $147 |
| Daiichi Sankyo Inc. | 6 | $143 |
| Bayer | 5 | $121 |
| E.r. Squibb & Sons, L.L.C. | 6 | $106 |
| Astellas Pharma US Inc | 1 | $90 |
| Novo Nordisk | 4 | $88 |
| Pfizer | 4 | $85 |
| Scpharmaceuticals Inc. | 5 | $76 |
| Amgen | 4 | $71 |
| Shockwave Medical, Inc | 1 | $16 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Getinge USA Sales, LLC | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WAINUA$19,277
- LOKELMA$4,400
- Ensite Cardiac Mapping System$1,325
- Barostim Neo System$906
- OPTIMIZER$759
- CardioMEMS HF System$453
- FARXIGA$252
- CARDIOMEMS$233
- HeartMate 3 Left Ventricular Dev$183
- TactiCath Quartz CFA Catheter$166
- Amplia MRI$145
- Connect HF$144
- MitraClip$133
- RESONATE$125
- TYVASO$124
- remede System$118
- Quadra Assura CRT Defibrillator$117
- HeartWare HVAD$113
- ONPATTRO$106
- LifeVest$105
How this compares
$36,270 in reported general payments places this provider in the 80th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 105 | $127,539 |
| EntrestoSacubitril/Valsartan | 93 | $86,370 |
| EliquisApixaban | 70 | $84,379 |
| FarxigaDapagliflozin Propanediol | 50 | $50,563 |
| Torsemide | 134 | $2,827 |
| Potassium Chloride | 77 | $1,995 |
| Bumetanide | 60 | $1,934 |
| Metoprolol Succinate | 96 | $1,202 |
| Amiodarone Hcl | 37 | $911 |
| Spironolactone | 99 | $578 |
| Atorvastatin Calcium | 65 | $569 |
| Losartan Potassium | 48 | $489 |
| Carvedilol | 80 | $478 |
| Hydralazine Hcl | 39 | $421 |
| Furosemide | 100 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $264 | $127,539105 claims |
| NovartisEntresto | $363 | $86,37093 claims |
| PfizerEliquis | $85 | $84,37970 claims |
| AstraZenecaFarxiga | $25,124 | $50,56350 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in Brooklyn
- Norbert MoskovitsBrooklyn$159K
- Laurie LetarteBrooklyn$20K
- Shudhanshu AlishettiBrooklyn$13K
- Johanna ContrerasNew York$534K
- Scott FeitellRochester$422K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Gregg LanierHawthorne$239K
- Michelle BloomMineola$166K
- Stephen PanValhalla$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.